Core Viewpoint - MicroPort Scientific Corporation-B (02252) has seen a significant increase in its stock price, rising over 4% and currently trading at 27.66 HKD with a transaction volume of 1.59 billion HKD, following the announcement of a substantial increase in order volume for its core products [1] Group 1: Order Volume and Product Performance - The cumulative order volume for MicroPort's core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 230 units [1] - The TiMAY endoscopic surgical robot has achieved over 160 commercial orders globally, with nearly 120 new orders acquired this year [1] - By 2025, TiMAY is projected to rank among the top two in global order volume according to public statistics [1] Group 2: Market Penetration - In the domestic market, TiMAY has made significant progress in top public hospitals and high-end private hospitals, with 23% of installed hospitals being among the top 100 hospitals and over 90% being tertiary hospitals [1] - The company has established a high-quality installation pattern driven by clinical value and professional capability accumulation [1] - Internationally, TiMAY's market presence has expanded to over 40 countries and regions across Asia, Europe, Africa, Oceania, and South America, gaining recognition from local top institutions [1] Group 3: Sales and Installation Achievements - TiMAY has achieved "multiple sales and installations in multiple hospitals" in 15 countries, indicating a trend towards normalized, networked, and scaled usage within mature healthcare systems globally [1]